Annual CFF
-$45.46 M
+$289.57 M+86.43%
March 31, 2024
Summary
- As of February 6, 2025, RDY annual cash flow from financing activities is -$45.46 million, with the most recent change of +$289.57 million (+86.43%) on March 31, 2024.
- During the last 3 years, RDY annual CFF has fallen by -$41.45 million (-1034.46%).
- RDY annual CFF is now -107.35% below its all-time high of $618.26 million, reached on March 31, 2006.
Performance
RDY Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$4.42 M
-$187.88 M-97.70%
December 31, 2024
Summary
- As of February 6, 2025, RDY quarterly cash flow from financing activities is $4.42 million, with the most recent change of -$187.88 million (-97.70%) on December 31, 2024.
- Over the past year, RDY quarterly CFF has dropped by -$109.95 million (-96.14%).
- RDY quarterly CFF is now -99.27% below its all-time high of $608.03 million, reached on March 31, 2006.
Performance
RDY Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$304.42 M
-$59.73 M-16.40%
December 31, 2024
Summary
- As of February 6, 2025, RDY TTM cash flow from financing activities is $304.42 million, with the most recent change of -$59.73 million (-16.40%) on December 31, 2024.
- Over the past year, RDY TTM CFF has increased by +$217.55 million (+250.41%).
- RDY TTM CFF is now -57.54% below its all-time high of $716.91 million, reached on December 31, 2006.
Performance
RDY TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
RDY Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +86.4% | -96.1% | +250.4% |
| 3 y3 years | -1034.5% | -96.1% | +250.4% |
| 5 y5 years | +85.1% | +102.0% | +159.0% |
RDY Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -1034.5% | +86.4% | -97.7% | +102.9% | -16.4% | +190.9% |
| 5 y | 5-year | -1034.5% | +87.2% | -97.7% | +102.0% | -16.4% | +159.0% |
| alltime | all time | -107.3% | +87.2% | -99.3% | +102.0% | -57.5% | +159.0% |
Dr Reddys Laboratories Limited Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | - | $4.42 M(-97.7%) | $304.42 M(-16.4%) |
| Sep 2024 | - | $192.30 M(+68.1%) | $364.16 M(+319.2%) |
| Jun 2024 | - | $114.37 M(-1816.3%) | $86.88 M(-291.1%) |
| Mar 2024 | -$45.46 M(-86.4%) | -$6.66 M(-110.4%) | -$45.46 M(-54.1%) |
| Dec 2023 | - | $64.15 M(-175.5%) | -$99.05 M(-33.0%) |
| Sep 2023 | - | -$84.98 M(+373.0%) | -$147.85 M(-30.6%) |
| Jun 2023 | - | -$17.97 M(-70.2%) | -$213.01 M(-36.4%) |
| Mar 2023 | -$335.03 M(+930.4%) | -$60.26 M(-492.3%) | -$335.03 M(+61.9%) |
| Dec 2022 | - | $15.36 M(-110.2%) | -$206.97 M(-19.1%) |
| Sep 2022 | - | -$150.14 M(+7.3%) | -$255.82 M(+25.9%) |
| Jun 2022 | - | -$139.98 M(-306.5%) | -$203.16 M(+524.8%) |
| Mar 2022 | -$32.51 M(+711.4%) | $67.79 M(-302.4%) | -$32.51 M(-296.6%) |
| Dec 2021 | - | -$33.49 M(-65.6%) | $16.54 M(-131.6%) |
| Sep 2021 | - | -$97.48 M(-417.9%) | -$52.26 M(-22.7%) |
| Jun 2021 | - | $30.66 M(-73.8%) | -$67.60 M(+1587.3%) |
| Mar 2021 | -$4.01 M(-98.9%) | $116.84 M(-214.2%) | -$4.01 M(-91.3%) |
| Dec 2020 | - | -$102.28 M(-9.3%) | -$46.02 M(-73.0%) |
| Sep 2020 | - | -$112.82 M(-219.7%) | -$170.19 M(+0.5%) |
| Jun 2020 | - | $94.26 M(+26.0%) | -$169.42 M(-52.2%) |
| Mar 2020 | -$354.28 M(+16.2%) | $74.83 M(-133.0%) | -$354.28 M(-31.4%) |
| Dec 2019 | - | -$226.45 M(+102.1%) | -$516.13 M(+18.9%) |
| Sep 2019 | - | -$112.05 M(+23.7%) | -$434.18 M(+5.1%) |
| Jun 2019 | - | -$90.61 M(+4.1%) | -$413.28 M(+35.6%) |
| Mar 2019 | -$304.86 M(+342.7%) | -$87.02 M(-39.8%) | -$304.86 M(-2.1%) |
| Dec 2018 | - | -$144.51 M(+58.5%) | -$311.40 M(+135.6%) |
| Sep 2018 | - | -$91.15 M(-611.7%) | -$132.16 M(+85.9%) |
| Jun 2018 | - | $17.81 M(-119.0%) | -$71.07 M(+3.2%) |
| Mar 2018 | -$68.87 M(+25.1%) | -$93.55 M(-369.3%) | -$68.87 M(-19.3%) |
| Dec 2017 | - | $34.73 M(-215.5%) | -$85.33 M(-50.7%) |
| Sep 2017 | - | -$30.07 M(-250.2%) | -$173.03 M(-216.4%) |
| Jun 2017 | - | $20.02 M(-118.2%) | $148.67 M(-370.0%) |
| Mar 2017 | -$55.06 M(-78.8%) | -$110.01 M(+107.7%) | -$55.06 M(-255.9%) |
| Dec 2016 | - | -$52.97 M(-118.2%) | $35.32 M(-15.5%) |
| Sep 2016 | - | $291.63 M(-258.7%) | $41.81 M(-110.6%) |
| Jun 2016 | - | -$183.71 M(+835.5%) | -$393.64 M(+51.5%) |
| Mar 2016 | -$259.89 M(+285.8%) | -$19.64 M(-57.7%) | -$259.89 M(+48.8%) |
| Dec 2015 | - | -$46.47 M(-67.7%) | -$174.67 M(+78.2%) |
| Sep 2015 | - | -$143.82 M(+187.9%) | -$98.01 M(+60.2%) |
| Jun 2015 | - | -$49.96 M(-176.2%) | -$61.17 M(-9.2%) |
| Mar 2015 | -$67.37 M(+1770.6%) | $65.58 M(+117.2%) | -$67.37 M(-65.3%) |
| Dec 2014 | - | $30.19 M(-128.2%) | -$194.10 M(-10.2%) |
| Sep 2014 | - | -$106.98 M(+90.5%) | -$216.10 M(+66.0%) |
| Jun 2014 | - | -$56.16 M(-8.2%) | -$130.19 M(+3515.2%) |
| Mar 2014 | -$3.60 M(-89.1%) | -$61.15 M(-846.2%) | -$3.60 M(-109.0%) |
| Dec 2013 | - | $8.19 M(-138.9%) | $39.90 M(+5.6%) |
| Sep 2013 | - | -$21.08 M(-129.9%) | $37.80 M(+113.9%) |
| Jun 2013 | - | $70.43 M(-499.1%) | $17.67 M(-153.6%) |
| Mar 2013 | -$32.97 M | -$17.65 M(-389.7%) | -$32.97 M(-73.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2012 | - | $6.09 M(-114.8%) | -$121.99 M(+263.6%) |
| Sep 2012 | - | -$41.21 M(-308.2%) | -$33.55 M(-135.9%) |
| Jun 2012 | - | $19.79 M(-118.6%) | $93.43 M(+19.4%) |
| Mar 2012 | $78.27 M(-1045.2%) | -$106.67 M(-212.8%) | $78.27 M(-70.4%) |
| Dec 2011 | - | $94.53 M(+10.2%) | $264.19 M(+75.8%) |
| Sep 2011 | - | $85.78 M(+1751.1%) | $150.28 M(+1690.8%) |
| Jun 2011 | - | $4.63 M(-94.2%) | $8.39 M(-201.3%) |
| Mar 2011 | -$8.28 M(-92.6%) | $79.25 M(-508.9%) | -$8.28 M(-57.5%) |
| Dec 2010 | - | -$19.38 M(-65.5%) | -$19.48 M(-51.3%) |
| Sep 2010 | - | -$56.11 M(+366.1%) | -$40.03 M(-6.9%) |
| Jun 2010 | - | -$12.04 M(-117.7%) | -$42.98 M(-61.6%) |
| Mar 2010 | -$112.05 M(+103.5%) | $68.05 M(-270.4%) | -$112.05 M(-48.0%) |
| Dec 2009 | - | -$39.93 M(-32.4%) | -$215.54 M(+21.3%) |
| Sep 2009 | - | -$59.07 M(-27.2%) | -$177.66 M(+125.4%) |
| Jun 2009 | - | -$81.10 M(+128.9%) | -$78.82 M(+43.1%) |
| Mar 2009 | -$55.06 M(-71.9%) | -$35.44 M(+1618.6%) | -$55.06 M(+600.4%) |
| Dec 2008 | - | -$2.06 M(-105.2%) | -$7.86 M(-46.0%) |
| Sep 2008 | - | $39.78 M(-169.4%) | -$14.55 M(-72.1%) |
| Jun 2008 | - | -$57.34 M(-587.5%) | -$52.10 M(-73.5%) |
| Mar 2008 | -$196.26 M(-603.1%) | $11.76 M(-234.3%) | -$196.26 M(-29.4%) |
| Dec 2007 | - | -$8.75 M(-492.2%) | -$277.89 M(+94.2%) |
| Sep 2007 | - | $2.23 M(-101.1%) | -$143.12 M(-15.3%) |
| Jun 2007 | - | -$201.50 M(+188.4%) | -$168.90 M(-532.9%) |
| Mar 2007 | $39.01 M(-93.7%) | -$69.86 M(-155.4%) | $39.01 M(-94.6%) |
| Dec 2006 | - | $126.01 M(-635.2%) | $716.91 M(+23.2%) |
| Sep 2006 | - | -$23.55 M(-467.4%) | $582.04 M(-2.8%) |
| Jun 2006 | - | $6.41 M(-98.9%) | $598.61 M(-3.2%) |
| Mar 2006 | $618.26 M(+1333.4%) | $608.03 M(-6969.3%) | $618.26 M(+2138.1%) |
| Dec 2005 | - | -$8.85 M(+26.8%) | $27.62 M(-46.7%) |
| Sep 2005 | - | -$6.98 M(-126.8%) | $51.79 M(+75.0%) |
| Jun 2005 | - | $26.07 M(+49.9%) | $29.60 M(-31.4%) |
| Mar 2005 | $43.13 M(-625.6%) | $17.39 M(+13.6%) | $43.13 M(+47.9%) |
| Dec 2004 | - | $15.31 M(-152.5%) | $29.17 M(+197.4%) |
| Sep 2004 | - | -$29.18 M(-173.7%) | $9.81 M(-69.6%) |
| Jun 2004 | - | $39.60 M(+1056.0%) | $32.27 M(-493.2%) |
| Mar 2004 | -$8.21 M(+160.5%) | $3.43 M(-184.6%) | -$8.21 M(-13.9%) |
| Dec 2003 | - | -$4.05 M(-39.7%) | -$9.53 M(+44.6%) |
| Sep 2003 | - | -$6.71 M(+668.6%) | -$6.59 M(+72.5%) |
| Jun 2003 | - | -$873.20 K(-141.5%) | -$3.82 M(+21.3%) |
| Mar 2003 | -$3.15 M(-110.6%) | $2.10 M(-289.5%) | -$3.15 M(-53.7%) |
| Dec 2002 | - | -$1.11 M(-71.8%) | -$6.80 M(-69.5%) |
| Sep 2002 | - | -$3.94 M(+1847.3%) | -$22.27 M(+4.1%) |
| Jun 2002 | - | -$202.40 K(-86.9%) | -$21.39 M(-171.9%) |
| Mar 2002 | $29.73 M(-1656.4%) | -$1.55 M(-90.7%) | $29.73 M(-4.9%) |
| Dec 2001 | - | -$16.58 M(+441.9%) | $31.28 M(-34.6%) |
| Sep 2001 | - | -$3.06 M(-106.0%) | $47.86 M(-6.0%) |
| Jun 2001 | - | $50.92 M | $50.92 M |
| Mar 2001 | -$1.91 M | - | - |
FAQ
- What is Dr Reddys Laboratories Limited annual cash flow from financing activities?
- What is the all time high annual CFF for Dr Reddys Laboratories Limited?
- What is Dr Reddys Laboratories Limited annual CFF year-on-year change?
- What is Dr Reddys Laboratories Limited quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Dr Reddys Laboratories Limited?
- What is Dr Reddys Laboratories Limited quarterly CFF year-on-year change?
- What is Dr Reddys Laboratories Limited TTM cash flow from financing activities?
- What is the all time high TTM CFF for Dr Reddys Laboratories Limited?
- What is Dr Reddys Laboratories Limited TTM CFF year-on-year change?
What is Dr Reddys Laboratories Limited annual cash flow from financing activities?
The current annual CFF of RDY is -$45.46 M
What is the all time high annual CFF for Dr Reddys Laboratories Limited?
Dr Reddys Laboratories Limited all-time high annual cash flow from financing activities is $618.26 M
What is Dr Reddys Laboratories Limited annual CFF year-on-year change?
Over the past year, RDY annual cash flow from financing activities has changed by +$289.57 M (+86.43%)
What is Dr Reddys Laboratories Limited quarterly cash flow from financing activities?
The current quarterly CFF of RDY is $4.42 M
What is the all time high quarterly CFF for Dr Reddys Laboratories Limited?
Dr Reddys Laboratories Limited all-time high quarterly cash flow from financing activities is $608.03 M
What is Dr Reddys Laboratories Limited quarterly CFF year-on-year change?
Over the past year, RDY quarterly cash flow from financing activities has changed by -$109.95 M (-96.14%)
What is Dr Reddys Laboratories Limited TTM cash flow from financing activities?
The current TTM CFF of RDY is $304.42 M
What is the all time high TTM CFF for Dr Reddys Laboratories Limited?
Dr Reddys Laboratories Limited all-time high TTM cash flow from financing activities is $716.91 M
What is Dr Reddys Laboratories Limited TTM CFF year-on-year change?
Over the past year, RDY TTM cash flow from financing activities has changed by +$217.55 M (+250.41%)